Is IFF a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Food Ingredients sale and the capital return attached to it, with revenue (ttm, all businesses) at ~$10.8B. The bear case rests on the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Analysts covering it are spread from $76.00 to $105.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $76.00, -9.7% from the $84.18 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The Food Ingredients sale and the capital return attached to it. On May 29, 2026 IFF agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners at an enterprise value of about $4.3 billion, retaining a ~10% minority stake and expecting ~$3.8 billion of net cash proceeds. The most optimistic analyst target on IFF is $105.00, +24.7% from the $84.18 price. That figure is only reachable if this thesis works close to its best case.

The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Stranded costs are the near-term execution problem: roughly $3.2 billion of sales and ~$520 million of EBITDA leave the company, and the overhead that supported them has to be removed for the stated margin uplift to be real. GAAP earnings remain thin relative to the market value, with trailing net income of ~$277 million against a ~$21.5 billion capitalization, because ~$948 million of annual depreciation and amortization and a string of disposal charges sit between EBITDA and reported profit. Goodwill of ~$8.1 billion and intangibles of ~$3.7 billion still make up a large share of a ~$14.0 billion equity base that already absorbed multi-billion-dollar impairments in 2022 and 2023, so further writedowns are possible if end markets soften. Antitrust exposure is also open: European Commission, UK CMA and Swiss inspections of fragrance pricing continue, and while IFF settled the U.S. civil class actions for roughly $43 million in provisions, an Israeli class action over a Frutarom-era bonus was certified in September 2025 with a rehearing motion still pending. The most pessimistic published target is $76.00, -9.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

A global supplier of flavors, fragrances, enzymes and cultures to food, beverage, home care and personal care manufacturers.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Food Ingredients sale and the capital return attached to it) stalling in the reported numbers rather than in the narrative, the risk above (the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

IFF supplies taste, scent and functional ingredients to other manufacturers rather than selling to consumers directly. That covers flavor systems for beverages, dairy, snacks and savory foods, fine and consumer fragrances, fragrance ingredients, and a biosciences portfolio of enzymes, cultures, probiotics and soy proteins. Its products end up in soft drinks, perfumes, detergents, supplements and animal nutrition under other companies' brands.

Food Ingredients was the lowest-margin part of the portfolio, and selling it lifts group adjusted operating EBITDA margin from about 19.7% to about 20.9% on the second quarter numbers. The May 2026 agreement with CVC Capital Partners values the unit at roughly $4.3 billion and should yield about $3.8 billion of net cash, with IFF keeping a ~10% stake. Management intends to use the money for more than $1 billion of debt reduction and a $2.5 billion buyback.

Most of it is done. The 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division pushed leverage above 4x, and a series of disposals including Pharma Solutions to Roquette and Cosmetic Ingredients to Clariant brought net debt to ~$5.2 billion and leverage to ~2.51x by June 30, 2026. That sits well inside the 3.75x credit agreement covenant, and the Food Ingredients proceeds are earmarked to take it lower.